{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T11:12:44Z","timestamp":1758280364488},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2002,9,27]],"date-time":"2002-09-27T00:00:00Z","timestamp":1033084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Physiologica Scandinavica"],"published-print":{"date-parts":[[2002,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>In a randomized, double\u2010blind trial in 3086 patients with unstable angina pectoris or non\u2010Q wave myocardial infarction we investigated if 80\u2003mg of atorvastatin daily could improve outcome of cardiovascular events during a short period of time (16\u2003weeks) compared with placebo. Baseline LDL cholesterol was 3.2\u2003mmol\u2003L<jats:sup>\u22121<\/jats:sup> (124\u2003mg\u2003dL<jats:sup>\u22121<\/jats:sup>) and decreased by 40% to 1.9\u2003mmol\u2003L<jats:sup>\u22121<\/jats:sup> (72\u2003mg\u2003dL<jats:sup>\u22121<\/jats:sup>) during atorvastatin treatment. The primary endpoint, which was a composite of death, non\u2010fatal acute myocardial infarction, cardiac arrest with resuscitation or recurrent symptomatic myocardial ischaemia with objective evidence and requiring emergency rehospitalization occurred in 228 patients (14.8%) in the atorvastatin group and 269 patients (17.4%) in the placebo group. The relative risk was0.84 and 95% confidence interval was 0.70\u20131.00 (<jats:italic>P<\/jats:italic>\u2003=\u20030.048). Thus for patients with acute coronary syndromes, lipid\u2010lowering therapy with high dose atorvastatin reduces recurrent ischaemic events in the short\u2010term. A possible mechanism behind this rapid clinical effect induced by statin treatment is on inflammatory processes. Recent studies strongly suggest that acute T\u2010cell activation is involved in the pathogenesis of unstable angina. In another study we investigated whether circulating T cells showed signs of activation in patients with stable angina pectoris (SA). Systemic venous blood samples were taken from 38 men with SA and 42 healthy controls. The T\u2010cell receptor expression was assessed by three\u2010colour flow cytometry using monoclonal antibodies against CD3,CD4, CD8, CD25 and human leucocyte antigen (HLA)\u2010DR. Soluble interleukin\u20102 receptor (sIL\u20102R) was measured as the circulating form in serum. Levels of circulating CD3+ and CD4+ T cells tended to be higher in patients compared with controls. Patients were also shown to have a significant increase in CD4+ T cells expressing the activation markers CD25 (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05) and HLA\u2010DR (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01). Furthermore, serum levels of sIL\u20102R were significantly higher (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001) in patients than in controls. We also observed that the T\u2010cell response was more pronounced in patients without simvastatin treatment (<jats:italic>n<\/jats:italic>\u2003=\u200318) compared with simvastatin\u2010treated patients (<jats:italic>n<\/jats:italic>\u2003=\u200320). In conclusion, our findings indicate that a continuous immune system activation takes place in patients with chronic angina pectoris, predominantly involving proliferation of CD4+ T cells. Statin treatment seems to be able to decrease this inflammatory response.<\/jats:p>","DOI":"10.1046\/j.1365-201x.2002.01017.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:34:42Z","timestamp":1047353682000},"page":"147-150","source":"Crossref","is-referenced-by-count":15,"title":["Are early clinical effects of cholesterol lowering mediated through effects on inflammation?"],"prefix":"10.1111","volume":"176","author":[{"given":"A. G.","family":"Olsson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. G.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Jonasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Linderfalk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,9,27]]},"reference":[{"key":"e_1_2_2_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.2.276"},{"key":"e_1_2_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00410-0"},{"key":"e_1_2_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00771-3"},{"key":"e_1_2_2_5_1","first-page":"387","article-title":"The role of isoprenoids in vascular smooth muscle cells: potential benefits of statins unrelated to cholesterol lowering","volume":"10","author":"Hughes A.","year":"1996","journal-title":"J Hum Hypertension"},{"key":"e_1_2_2_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.15.1933"},{"key":"e_1_2_2_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.6.2.131"},{"key":"e_1_2_2_8_1","doi-asserted-by":"crossref","unstructured":"Jonasson L. Linderfalk C. Olsson J. Wikby A.&Olsson A.2001.Systemic T\u2010cell activation in stable angina pectoris.Am J Cardiol89 754\u2013756.","DOI":"10.1016\/S0002-9149(01)02348-7"},{"key":"e_1_2_2_9_1","first-page":"S51","article-title":"Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis","volume":"45","author":"Kasiske B.","year":"1994","journal-title":"Kidney International"},{"key":"e_1_2_2_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199408183310701"},{"key":"e_1_2_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(99)00104-5"},{"key":"e_1_2_2_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.7.1806"},{"key":"e_1_2_2_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.5.1126"},{"key":"e_1_2_2_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.94.6.1239"},{"key":"e_1_2_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4889(90)90185-G"},{"key":"e_1_2_2_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106283442601"},{"key":"e_1_2_2_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.9.839"},{"key":"e_1_2_2_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610033351401"},{"key":"e_1_2_2_19_1","first-page":"1383","article-title":"Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease (the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Study Group","year":"1994","journal-title":"Lancet"},{"key":"e_1_2_2_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.13.1711"},{"key":"e_1_2_2_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811053391902"}],"container-title":["Acta Physiologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-201X.2002.01017.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-201X.2002.01017.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-201X.2002.01017.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T01:10:30Z","timestamp":1697505030000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-201X.2002.01017.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9,27]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["10.1046\/j.1365-201X.2002.01017.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-201x.2002.01017.x","archive":["Portico"],"relation":{},"ISSN":["0001-6772","1365-201X"],"issn-type":[{"value":"0001-6772","type":"print"},{"value":"1365-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,9,27]]}}}